Drug intelligence / Profile preview

EPI-011

Development stage: Preclinical
Lead developer: EpiBiotech
Modality: Small Molecules
Administration: Intralesional

Overview

EPI-011 is a synthetic small molecule drug candidate developed by Epibiotech for the treatment of chemotherapy-induced alopecia (CIA). The compound is designed to exert anti-inflammatory and anti-fibrotic effects to prevent or mitigate hair loss resulting from chemotherapy. Currently in the preclinical stage, EPI-011 represents a pharmacological approach to protecting hair follicles from the damage typically induced by cytotoxic agents.

Other names: EPI-011EPI011EPI 011

Targets

AR-AF1 (Androgen receptor N-terminal transactivation domain AF-1)

Beyond the preview

Go deeper on EPI-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPI-011.

Explore the full profile